First-line anti-TB drug.
It has bacterial growth-inhibiting action.
It is used in adults and children in combination with other anti-TB drugs for treatment of all types and localizations of tuberculosis (including those resistant to anti-TB drugs).
Resistance of Mycobacterium tuberculosis to Inbutol develops slowly.
The use of Inbutol (100 % bioavailability) at the hospital stage of treatment instead of ethambutol tablets (77 % bioavailability) helps reduce the dose of the drug while maintaining high efficacy of treatment and reduces the risk of side effects from TB chemotherapy.